Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | YAP1 | P46937 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 4/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25323981 | 1.00 | KDM4E (0.46) | KDM4EYAP1ALDH1A1LMNAKCNH2 | |
| SCHEMBL30551277 | 0.97 | YAP1 (0.44) | KDM4EYAP1ALDH1A1LMNAKCNH2 | |
| SCHEMBL25322853 | 0.94 | YAP1 (0.42) | KDM4EYAP1ALDH1A1LMNAKCNH2 | |
| SCHEMBL24367691 | 0.85 | RIPK1 (0.50) | KCNH2PRMT5GPR119 | |
| SCHEMBL25321789 | 0.83 | KCNH2 (0.54) | KDM4EALDH1A1LMNAKCNH2PRMT5 | |
| SCHEMBL25321784 | 0.83 | KCNH2 (0.54) | KDM4EALDH1A1LMNAKCNH2PRMT5 | |
| SCHEMBL25326414 | 0.82 | PRMT5 (0.47) | LMNAPRMT5 | |
| SCHEMBL24365995 | 0.82 | PRMT5 (0.47) | LMNAPRMT5 | |
| SCHEMBL29081437 | 0.82 | PRMT5 (0.47) | LMNAPRMT5 | |
| SCHEMBL29477677 | 0.82 | PRMT5 (0.47) | LMNAPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | KDM4E 1882/4885YAP1 2812/4885ALDH1A1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.